Loading…
Clinical characteristics of patients with late-onset multiple sclerosis
We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertai...
Saved in:
Published in: | Journal of neurology 2008-05, Vol.255 (5), p.697-702 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03 |
---|---|
cites | cdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03 |
container_end_page | 702 |
container_issue | 5 |
container_start_page | 697 |
container_title | Journal of neurology |
container_volume | 255 |
creator | Kis, B. Rumberg, B. Berlit, P. |
description | We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p < 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation. |
doi_str_mv | 10.1007/s00415-008-0778-x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20780266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20780266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</originalsourceid><addsrcrecordid>eNp1kE2LFDEQhoMo7uzqD_AijaC3aOWjO52jDLorLHjRc0hnKm6WTPeYSuP6780wgwuCpzrUU1VvPYy9EvBeAJgPBKBFzwFGDsaM_OEJ2witJBe6t0_ZBpQG3qteX7BLontoYGs8ZxdilKNSVm_Y9TanOQWfu3Dniw8VS6KaAnVL7A6-Jpwrdb9Sveuyr8iXmbB2-zXXdMjYUchYFkr0gj2LPhO-PNcr9v3zp2_bG3779frL9uMtD1pB5bpHaycQaMxu8rvByN1ke2Em0eJE22th7dDSAQ5D9MrHaJS3quEGBURQV-zdae-hLD9XpOr2iQLm7GdcVnISzAhyGBr45h_wflnL3LI5KUahtBllg8QJCu0JKhjdoaS9L7-dAHdU7E6KXTPnjordQ5t5fV68TnvcPU6cnTbg7Rnw1MTG4ueQ6C8nQStr4fiKPHHUWvMPLI8J_3_9D85dk2Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218134782</pqid></control><display><type>article</type><title>Clinical characteristics of patients with late-onset multiple sclerosis</title><source>Springer Nature</source><creator>Kis, B. ; Rumberg, B. ; Berlit, P.</creator><creatorcontrib>Kis, B. ; Rumberg, B. ; Berlit, P.</creatorcontrib><description>We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p < 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-008-0778-x</identifier><identifier>PMID: 18283394</identifier><identifier>CODEN: JNRYA9</identifier><language>eng</language><publisher>Darmstadt: Steinkopff-Verlag</publisher><subject>Adolescent ; Adult ; Age Factors ; Age of Onset ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Brain - pathology ; Brain - physiopathology ; Central Nervous System - pathology ; Central Nervous System - physiopathology ; Cohort Studies ; Diagnostic Errors ; Disease Progression ; Drug Resistance ; Evoked Potentials ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Movement Disorders - diagnosis ; Movement Disorders - epidemiology ; Movement Disorders - physiopathology ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - physiopathology ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Chronic Progressive - diagnosis ; Multiple Sclerosis, Chronic Progressive - epidemiology ; Multiple Sclerosis, Chronic Progressive - physiopathology ; Multiple Sclerosis, Relapsing-Remitting - diagnosis ; Multiple Sclerosis, Relapsing-Remitting - epidemiology ; Multiple Sclerosis, Relapsing-Remitting - physiopathology ; Neurology ; Neuroradiology ; Neurosciences ; Oligoclonal Bands - cerebrospinal fluid ; Original Communication ; Retrospective Studies ; Severity of Illness Index ; Spinal Cord - pathology ; Spinal Cord - physiopathology ; Steroids - therapeutic use</subject><ispartof>Journal of neurology, 2008-05, Vol.255 (5), p.697-702</ispartof><rights>Steinkopff-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</citedby><cites>FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20439900$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18283394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kis, B.</creatorcontrib><creatorcontrib>Rumberg, B.</creatorcontrib><creatorcontrib>Berlit, P.</creatorcontrib><title>Clinical characteristics of patients with late-onset multiple sclerosis</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p < 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Brain - physiopathology</subject><subject>Central Nervous System - pathology</subject><subject>Central Nervous System - physiopathology</subject><subject>Cohort Studies</subject><subject>Diagnostic Errors</subject><subject>Disease Progression</subject><subject>Drug Resistance</subject><subject>Evoked Potentials</subject><subject>Female</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Movement Disorders - diagnosis</subject><subject>Movement Disorders - epidemiology</subject><subject>Movement Disorders - physiopathology</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - physiopathology</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Chronic Progressive - diagnosis</subject><subject>Multiple Sclerosis, Chronic Progressive - epidemiology</subject><subject>Multiple Sclerosis, Chronic Progressive - physiopathology</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - epidemiology</subject><subject>Multiple Sclerosis, Relapsing-Remitting - physiopathology</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Oligoclonal Bands - cerebrospinal fluid</subject><subject>Original Communication</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Spinal Cord - pathology</subject><subject>Spinal Cord - physiopathology</subject><subject>Steroids - therapeutic use</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kE2LFDEQhoMo7uzqD_AijaC3aOWjO52jDLorLHjRc0hnKm6WTPeYSuP6780wgwuCpzrUU1VvPYy9EvBeAJgPBKBFzwFGDsaM_OEJ2witJBe6t0_ZBpQG3qteX7BLontoYGs8ZxdilKNSVm_Y9TanOQWfu3Dniw8VS6KaAnVL7A6-Jpwrdb9Sveuyr8iXmbB2-zXXdMjYUchYFkr0gj2LPhO-PNcr9v3zp2_bG3779frL9uMtD1pB5bpHaycQaMxu8rvByN1ke2Em0eJE22th7dDSAQ5D9MrHaJS3quEGBURQV-zdae-hLD9XpOr2iQLm7GdcVnISzAhyGBr45h_wflnL3LI5KUahtBllg8QJCu0JKhjdoaS9L7-dAHdU7E6KXTPnjordQ5t5fV68TnvcPU6cnTbg7Rnw1MTG4ueQ6C8nQStr4fiKPHHUWvMPLI8J_3_9D85dk2Y</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Kis, B.</creator><creator>Rumberg, B.</creator><creator>Berlit, P.</creator><general>Steinkopff-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20080501</creationdate><title>Clinical characteristics of patients with late-onset multiple sclerosis</title><author>Kis, B. ; Rumberg, B. ; Berlit, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Brain - physiopathology</topic><topic>Central Nervous System - pathology</topic><topic>Central Nervous System - physiopathology</topic><topic>Cohort Studies</topic><topic>Diagnostic Errors</topic><topic>Disease Progression</topic><topic>Drug Resistance</topic><topic>Evoked Potentials</topic><topic>Female</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Movement Disorders - diagnosis</topic><topic>Movement Disorders - epidemiology</topic><topic>Movement Disorders - physiopathology</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - physiopathology</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Chronic Progressive - diagnosis</topic><topic>Multiple Sclerosis, Chronic Progressive - epidemiology</topic><topic>Multiple Sclerosis, Chronic Progressive - physiopathology</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - epidemiology</topic><topic>Multiple Sclerosis, Relapsing-Remitting - physiopathology</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Oligoclonal Bands - cerebrospinal fluid</topic><topic>Original Communication</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Spinal Cord - pathology</topic><topic>Spinal Cord - physiopathology</topic><topic>Steroids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kis, B.</creatorcontrib><creatorcontrib>Rumberg, B.</creatorcontrib><creatorcontrib>Berlit, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Proquest Health & Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kis, B.</au><au>Rumberg, B.</au><au>Berlit, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics of patients with late-onset multiple sclerosis</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>255</volume><issue>5</issue><spage>697</spage><epage>702</epage><pages>697-702</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><coden>JNRYA9</coden><abstract>We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p < 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.</abstract><cop>Darmstadt</cop><pub>Steinkopff-Verlag</pub><pmid>18283394</pmid><doi>10.1007/s00415-008-0778-x</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-5354 |
ispartof | Journal of neurology, 2008-05, Vol.255 (5), p.697-702 |
issn | 0340-5354 1432-1459 |
language | eng |
recordid | cdi_proquest_miscellaneous_20780266 |
source | Springer Nature |
subjects | Adolescent Adult Age Factors Age of Onset Aged Aged, 80 and over Biological and medical sciences Brain - pathology Brain - physiopathology Central Nervous System - pathology Central Nervous System - physiopathology Cohort Studies Diagnostic Errors Disease Progression Drug Resistance Evoked Potentials Female Humans Magnetic Resonance Imaging Male Medical sciences Medicine Medicine & Public Health Middle Aged Movement Disorders - diagnosis Movement Disorders - epidemiology Movement Disorders - physiopathology Multiple Sclerosis - diagnosis Multiple Sclerosis - epidemiology Multiple Sclerosis - physiopathology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Chronic Progressive - diagnosis Multiple Sclerosis, Chronic Progressive - epidemiology Multiple Sclerosis, Chronic Progressive - physiopathology Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - epidemiology Multiple Sclerosis, Relapsing-Remitting - physiopathology Neurology Neuroradiology Neurosciences Oligoclonal Bands - cerebrospinal fluid Original Communication Retrospective Studies Severity of Illness Index Spinal Cord - pathology Spinal Cord - physiopathology Steroids - therapeutic use |
title | Clinical characteristics of patients with late-onset multiple sclerosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A44%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20of%20patients%20with%20late-onset%20multiple%20sclerosis&rft.jtitle=Journal%20of%20neurology&rft.au=Kis,%20B.&rft.date=2008-05-01&rft.volume=255&rft.issue=5&rft.spage=697&rft.epage=702&rft.pages=697-702&rft.issn=0340-5354&rft.eissn=1432-1459&rft.coden=JNRYA9&rft_id=info:doi/10.1007/s00415-008-0778-x&rft_dat=%3Cproquest_cross%3E20780266%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218134782&rft_id=info:pmid/18283394&rfr_iscdi=true |